NCT00318799 - Impact of SH T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D01155E) on Hemostatic Parameters | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions

Pregnancy, Unplanned

Interventions

DRUG

EV/DNG (Qlaira, BAY86-5027, SH T00658ID)

per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 824: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo

DRUG

SH D01155E

per cycle: Days 1-21: 0.03 mg EE + 0.15 mg LNG; Days 22-28: Placebo

Trial Locations (1)

9713GZ

Dinox B.V., Groningen